Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

IntroductionAlzheimer’s disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no establ...

Full description

Saved in:

Bibliographic Details
Published in:	BMJ open Vol. 11; no. 6; p. e051343
Main Authors:	Kondo, Takayuki, Banno, Haruhiko, Okunomiya, Taro, Amino, Yoko, Endo, Kayoko, Nakakura, Akiyoshi, Uozumi, Ryuji, Kinoshita, Akemi, Tada, Harue, Morita, Satoshi, Ishikawa, Hidehiro, Shindo, Akihiro, Yasuda, Ken, Taruno, Yosuke, Maki, Takakuni, Suehiro, Takashi, Mori, Kohji, Ikeda, Manabu, Fujita, Koji, Izumi, Yuishin, Kanemaru, Kazutomi, Ishii, Kenji, Shigenobu, Kazue, Kutoku, Yumiko, Sunada, Yoshihide, Kawakatsu, Shinobu, Shiota, Shunji, Watanabe, Toshifumi, Uchikawa, Osamu, Takahashi, Ryosuke, Tomimoto, Hidekazu, Inoue, Haruhisa
Format:	Journal Article
Language:	English
Published:	London BMJ Publishing Group LTD 30-06-2021 BMJ Publishing Group
Series:	Protocol
Subjects:	Alzheimer's disease Angina pectoris Clinical trials Cognitive ability Dementia Double-blind studies Drug dosages Genes Informed consent Mental disorders Metabolism Mutation Neurology Pathology Patients Proteins Syphilis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!